Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsPhilip E. Pellett, Demetrio Sanchez-Martinez
Life of this patent
Estimating the term…
Abstract
Novel baculovirus expression vectors and recombinant antigens for detecting, type-specific herpes simplex virus (HSV) infection have been made. Diagnostic kits and assays for detecting type-specific HSV infection have been described. High level production of foreign proteins in substantially pure form are now made possible by the novel baculoviruses of the present invention.
Claims2
A diagnostic kit comprising containers separately containing recombinant baculovirus expressed herpes simplex virus gG-1 and herpes simplex virus gG-2 antigens in substantially pure form, wherein the herpes simplex virus gG-1 and herpes simplex virus gG-2 antigens are produced by employing a recombinant baculovirus having the 5' nontranslated leader sequence of the polyhedrin gene joined to the coding region of a foreign gene precisely at the translation initiation codon of the polyhedrin gene, without either missing any nucleotide present in said initiation codon or introducing any extraneous nucleotide at the initiation codon site.
A diagnostic assay for detecting type-specific herpes simplex virus infection comprising contacting a biological sample obtained from a person suspected of herpes simplex virus infection with substantially pure recombinant baculovirus expressed herpes simplex virus gG-1 and herpes simplex virus gG-2 antigens, wherein the herpes simplex virus gG-1 and herpes simplex virus gG-2 antigens are produced by employing a recombinant baculovirus having the 5' nontranslated leader sequence of the polyhedrin gene joined to the coding region of a foreign gene precisely at the translation initiation codon of the polyhedrin gene, without either missing any nucleotide present in said initiation codon or introducing any extraneous nucleotide at the initiation codon site, and detecting any immunocomplex formed, the formation of an immunocomplex with said herpes simplex virus gG-1 antigen being indicative of herpes simplex virus type 1 infection and the formation of an immunocomplex with said herpes simplex virus gG-2 antigen being indicative of herpes simplex virus type 2 infection.
Dependencies are inferred from the claim text.